Spironolactone Improves the All-Cause Mortality and Re-Hospitalization Rates in Acute Myocardial Infarction with Chronic Kidney Disease Patients

Background: Mineralocorticoid receptor antagonists (MRA) improve outcomes in chronic kidney disease (CKD) and acute myocardial infarction (AMI) patients. However, the lack of evidence regarding long-term clinical outcomes in the use of MRA, including spironolactone, in patients with AMI combined wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Xiang, Yao, Hui, Chen, Changxi, Kong, Shuting, Sun, Lingyue, Du, Leilei, Liang, Siqi, Gao, Zhan, Zheng, Gaoshu, Zheng, Minghua, Zhao, Chuhuan, Feng, Xiafei, Wu, Gaojun, Zhou, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201517/
https://www.ncbi.nlm.nih.gov/pubmed/34135751
http://dx.doi.org/10.3389/fphar.2021.632978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201517/
https://www.ncbi.nlm.nih.gov/pubmed/34135751
http://dx.doi.org/10.3389/fphar.2021.632978

Ejemplares similares